« Back
Home /
Ceftriaxone

Ceftriaxone

Item no.	HY-B0712-100mg
Manufacturer	MedChem Express
CASRN	73384-59-5
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 1 mg 25 mg 500 mg 50 mg 5 mg
Category	Food Safety Antibiotics Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.62
Citations	[1]Nahata MC, et al. Ceftriaxone: a third-generation cephalosporin. Drug Intell Clin Pharm. 1985 Dec;19(12):900-6.\|[2] Nassar H, et al. Molecular docking, molecular dynamics simulations and in vitro screening reveal cefixime and ceftriaxone as GSK3β covalent inhibitors. RSC Adv. 2023 Apr 11;13(17):11278-11290.\|[3]Zhang Y, et al. Ceftriaxone Protects Astrocytes from MPP(+) via Suppression of NF-κB/JNK/c-Jun Signaling. Mol Neurobiol. 2015 Aug;52(1):78-92.\|[4]Li X, et al. Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B. Carcinogenesis. 2012 Dec;33(12):2548-57.\|[5]Hakimizadeh E, et al. Ceftriaxone improves hepatorenal damages in mice subjected to D-galactose-induced aging. Life Sci. 2020 Oct 1;258:118119.\|[6]Uyanikgil Y, et al. Positive effects of ceftriaxone on pentylenetetrazol-induced convulsion model in rats. Int J Neurosci. 2016;126(1):70-5.\|[7]Gunduz O, et al. Anti-allodynic and anti-hyperalgesic effects of ceftriaxone in streptozocin-induced diabetic rats. Neurosci Lett. 2011 Mar 10;491(1):23-5. AMB Express. 2024 Dec 24;14(1):141. BMC Cancer. 2025 Jun 1;25(1):977. BMC Microbiol. 2025 Apr 29;25(1):257. Diagn Microbiol Infect Dis. 2025 Nov 4;114(2):117181. EBioMedicine. 2022 Apr;78:103943. Proc Natl Acad Sci U S A. 2025 Dec 2;122(48):e2524436122. Cell Chem Biol. 2024 May 20:S2451-9456(24)00179-X. Chemosphere. 2023 Dec:344:140353. Emerg Microbes Infect. 2024 Dec;13(1):2321981. Microbiol Spectr. 2025 Oct 16:e0160325. Nat Commun. 2022 Mar 2;13(1):1116.
Smiles	O=C(C(N12)=C(CSC(N(C)NC3=O)=NC3=O)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Ro 13-9904 (free acid)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	Antibiotic; Aurora Kinase; Bacterial; GSK-3
Manufacturer - HS Code	H302, H315, H319, H335
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	554.58
Product Description	Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis[1][2][3][4][5][6][7].
Manufacturer - Research Area	Cancer; Infection; Neurological Disease; Inflammation/Immunology; Metabolic Disease
Solubility	DMSO : 31.25 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Anti-infection; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR; Stem Cell/Wnt
Clinical information	Launched
Isoform	β-lactam
UNSPSC Code	12352005
Precautionary	H302, H315, H319, H335

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.